Deep Vein Thrombosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Deep Vein Thrombosis stocks.

Deep Vein Thrombosis Stocks Recent News

Date Stock Title
Oct 1 SNY Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sep 30 SNY Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 28 SNY Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 27 SNY Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 SNY Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 SNY Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 SNY Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sep 27 SNY Sanofi, Regeneron get additional Chinese approval for Dupixent
Sep 27 SNY Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Sep 27 SNY Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Sep 27 SNY Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Sep 27 SNY Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Sep 27 SNY Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Sep 27 SNY FDA, after delay, clears Regeneron and Sanofi drug for COPD
Sep 26 SNY Are Investors Undervaluing Sanofi (SNY) Right Now?
Sep 26 SNY Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
Deep Vein Thrombosis

Deep vein thrombosis (DVT), is the formation of a blood clot in a deep vein, most commonly the legs. Symptoms may include pain, swelling, redness, or warmth of the affected area. About half of cases have no symptoms. Complications may include pulmonary embolism, as a result of detachment of a clot which travels to the lungs, and post-thrombotic syndrome.Risk factors include recent surgery, cancer, trauma, lack of movement, obesity, smoking, hormonal birth control, pregnancy and the period following birth, antiphospholipid syndrome, and certain genetic conditions. Genetic factors include deficiencies of antithrombin, protein C, and protein S, and factor V Leiden mutation. The underlying mechanism typically involves some combination of decreased blood flow rate, increased tendency to clot, and injury to the blood vessel wall.Individuals suspected of having DVT may be assessed using a clinical prediction rule such as the Wells score. A D-dimer test may also be used to assist with excluding the diagnosis or to signal a need for further testing. Diagnosis is most commonly confirmed by ultrasound of the suspected veins. Together, DVT and pulmonary embolism are known as venous thromboembolism (VTE).Anticoagulation (blood thinners) is the standard treatment. Typical medications include low-molecular-weight heparin, warfarin, or a direct oral anticoagulant. Wearing graduated compression stockings may reduce the risk of post-thrombotic syndrome. Prevention may include early and frequent walking, calf exercises, aspirin, anticoagulants, graduated compression stockings, or intermittent pneumatic compression. The rate of DVTs increases from childhood to old age; in adulthood, about one in 1000 adults are affected per year. About 5% of people are affected by a VTE at some point in time.

Browse All Tags